Complete Story
 

11/06/2012

SYNRIBO (omacetaxine mepesuccinate)

Now Approved for CML

Teva Oncology announced the FDA approval of SYNRIBO^™ for Injection
for the treatment of adult patients with chronic or accelerated phase chronic
myeloid leukemia (CML) with resistance and/or intolerance to two or more
tyrosine kinase inhibitors (TKIs) READ MORE